This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent and sustained inhibition against the HER2–HER3 signaling while sparing EGFR activity, leading to a large therapeutic window. (December 2016)
Record Type:
Journal Article
Title:
TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent and sustained inhibition against the HER2–HER3 signaling while sparing EGFR activity, leading to a large therapeutic window. (December 2016)
Main Title:
TPC-107, a next generation, HER2 selective covalent inhibitor demonstrates potent and sustained inhibition against the HER2–HER3 signaling while sparing EGFR activity, leading to a large therapeutic window